Ultragenyx Pharmaceutical Inc Q1 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Malcolm A. Kuno - JPMorgan Chase & Co, Research Division - Analyst : This is actually a Malcolm Kuno on for Anupam. So looking ahead, is there anything that you would be looking for in Sarepta's AdComm panel next week that could read through to your broader gene therapy program?

Question: Carly Nicole Kenselaar - Citigroup Inc., Research Division - Analyst : This is Carly on for Yigal. We wanted to ask about the initial data for Wilson disease expected early next year. I guess, can you help put into context what you plan to show and what you believe would constitute a positive outcome from that part of the study?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Just considering the late-stage nature and potential approval cadence a number of your late-stage candidates in the next few years. I wanted to ask how you're thinking about leveraging and building on some of your ex U.S. and global footprint to address some of these markets where you maintain rights?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Great. And it looks like you have a pretty significant presence at ASGCT this year. Wondering if there's anything in particular you think we should be focusing on?